Consolidated Revenue 150.4B KRW, Operating Profit 3.56B KRW (YoY Decline)

Consolidated quarterly revenue 150.4B KRW, operating profit 3.56B KRW, net profit 4.48B KRW. YoY revenue down 17.4%, operating profit down 50%.
Separate quarterly revenue 3.44B KRW, operating profit 1.13B KRW, net profit 0.93B KRW.
Correction of executive concurrent positions: CEO Han Sang-cheol removed from Onconic Therapeutics position; Executive Director Seo Byeong-gu removed from Jeil Health Science auditor position.
Cash dividend of 70 won per share declared (up from 50 won prior year).
Consolidated net debt ratio 72.7% (slight improvement from 74.9% at year-end).
One pending lawsuit (claim amount 2.77B KRW, defendant).